API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Historical End-of-Day API Real-time Prices API Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 152 articles Forum Github 14 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. F /
  3. 8XB.F

Biocartis Group NV (8XB F) stock market data APIs

€0.2595 0(0%) as of October 30, 2024
Price chart is built with Anychart

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Biocartis Group NV Financial Data Overview

0.2595
0.2595
-
0.2595
0.2595
0.2595-0.2595
27 236 K
93 916 K
60 822 K
1.323
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '8XB',
Type: 'Common Stock',
Name: 'Biocartis Group NV',
Exchange: 'F',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Germany',
CountryISO: 'DE',
OpenFigi: NULL,
ISIN: 'BE0974281132',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Diagnostics & Research',
}

Biocartis Group NV Fundamental Data is available in our Financial Data APIs

  • Net Revenue 60 822 K
  • EBITDA -37 015 000
  • Earnings Per Share -0.92
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Biocartis Group NV Earnings via APIs

  • Latest Release NaN
  • EPS/Forecast NaN

Get Biocartis Group NV End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Biocartis Group NV latest news via APIs

Press release Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service Delivery

Biocartis NV PRESS RELEASE - INSIDE INFORMATION/ REGULATED INFORMATION 18 July 2023, 7:00 AM CEST Biocartis appoints George Cardoza as new CFOand Head of Service Delivery George Cardoza appointed...

Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

Biocartis NV PRESS RELEASE - REGULATED INFORMATION 30 June 2023, 7:00 CEST Disclosure of Outstanding Voting Securities Mechelen, Belgium, 30 June 2023– Biocartis Group NV (the "Company" or "Bioc...
News API is available at any package from $19.99 See full price
Get sample of News API
Do you have any questions?
support@eodhistoricaldata.com